NCT03359473 - Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2018

Primary Completion Date

November 19, 2019

Study Completion Date

November 19, 2019

Conditions

Cachexia

Interventions

DRUG

GSK2881078

GSK2881078 will be available as capsules for oral administration. GSK2881078 will be administered once daily by the oral route at a dose of 1 mg and 2mg to post-menopausal female subjects and male subjects, respectively.

DRUG

Matching Placebo

Subjects will be administered two capsules of GSK2881078 matching placebo once daily by the oral route.

Trial Locations (11)

19140

GSK Investigational Site, Philadelphia

22927

GSK Investigational Site, Großhansdorf

27262

GSK Investigational Site, High Point

29303

GSK Investigational Site, Spartanburg

32216

GSK Investigational Site, Jacksonville

60596

GSK Investigational Site, Frankfurt am Main

90502

GSK Investigational Site, Torrance

LE3 9QP

GSK Investigational Site, Leicester

UB9 6JH

GSK Investigational Site, Harefield

SW3 6HP

GSK Investigational Site, London

SE1 7EH

GSK Investigational Site, London, Greater London